The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral drug). Treatments will be randomly assigned to study patients. The main questions it aims to answer are the following: 1. Whether the proportion of men who undergo SUGAR have superior rate of attaining PSA nadir of \<= 0.2 compared to SBRT alone, and 2. Whether SUGAR is superior to historical rates of minimal clinically important decline (MCID) in sexual and hormonal function at 6 months for patients undergoing 6 months of androgen deprivation therapy (ADT) Men aged 18+ with cFIR/cgUIR will be enrolled. Specifically, patients must meet one of the following 2 criteria: 1) Gleason score must be Gleason 3+4 with a PSA \< 20 ng/mL, or 2) Gleason 6 (3+3) and PSA \> 10 ng/mL and \< 20 ng mL.
Sponsor: Yale University
You may qualify if…
- ✓ 1. Provision of signed and dated informed consent form
- ✓ 2. Stated willingness to comply with all study procedures and availability for the duration of the study
- ✓ 3. Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
- ✓ 4. Born assigned to Male gender, age 18 and above. Female identifying transgender or gender fluid are allowed on study provided they have not undergone testosterone suppressing therapy and were born with a prostate.
- ✓ 5. Has a serum testosterone at the Screening visit of \>100 ng/dL
- ✓ 6. Has a serum PSA concentration at the Screening visit of \> 0.2 ng/mL
- ✓ 7. Able to swallow pills and take medication orally (no documented inability to eat solids and swallow pills) and be willing to adhere to the daily regimen of medication (if assigned to the experimental arm).
- ✓ 8. For patients of reproductive potential: use of condoms or other methods (including abstinence) to ensure effective contraception with partner during radiotherapy and through 4 months after the last dose of the study drug or radiotherapy
You may not qualify if…
- ✕ 1. Current use of medications that cause QT prolongation
- ✕ 2. Known allergic reactions to relugolix
- ✕ 3. Treatment with another investigational drug or other intervention for prostate cancer within 30 days of enrollment
- ✕ 4. Ulcerative colitis or other inflammatory bowel disease history
- ✕ 5. Connective tissue disease such as lupus, scleroderma, or dermatomyositis
- ✕ 6. GNRH antagonist therapy or SBRT to the prostate are medically contraindicated or not tolerated
- ✕ 7. History of long QT syndrome documented in the medical record
- ✕ 8. The following ECG abnormalities are excluded:
Where it's recruiting
Source: ClinicalTrials.gov · NCT06111781 · last updated 2026-07-21